Localized PD-1 CAR T therapy reprograms neuroinflammation
Cell · 2026
DOI: 10.1016/j.cell.2026.06.036 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cell, 2026. Verfasst von Rotem Shalita und 30 weiteren Autor:innen. Beteiligte Einrichtung: Department of Systems Immunology, Weizmann Institute of Science, Rehovot, Israel. Hauptthemen laut MEDLINE: Programmed Cell Death 1 Receptor, Multiple Sclerosis, Neuroinflammatory Diseases, Immunotherapy, Adoptive. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 127 Literaturangaben. Gefördert von: European Research Council.
Abstract (Originalsprache)
B cell-depleting therapies are effective in multiple sclerosis (MS), yet some patients relapse, underscoring the need for more precise interventions. To identify new therapeutic targets, we generated a single-cell RNA sequencing (scRNA-seq) atlas of cerebrospinal fluid (CSF), brain, and blood from non-inflammatory controls and patients with MS or other neuroinflammatory diseases. We found disease-associated enrichment of class-switched immunoglobulin G+ (IgG+) B cells and plasma cells in MS CSF. Unbiased analysis identified a rare disease-enriched subset of activated, T cell receptor (TCR)-restricted, PD-1+ T follicular helper-like cells with B cell-recruiting features. To target this population, we developed PD-1-directed chimeric antigen receptor (CAR) T cells that selectively depleted pathogenic PD-1+ CD4 T cells and locally released IL-10. This strategy attenuated central nervous system (CNS) inflammation, reprogrammed the local immune milieu, and improved clinical outcomes across murine neuroinflammation models. These findings define a CNS-localized adaptive immune circuit in MS and nominate programmable PD-1 CAR T cells as a strategy to disrupt it.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Systems Immunology, Weizmann Institute of Science, Rehovot, Israel.
- Department of Systems Immunology, Weizmann Institute of Science, Rehovot, Israel; Department of Medicine, Hadassah Medical Center, Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem, Israel.
- Institute of Clinical Neuroimmunology, University Hospital Ludwig-Maximilians-Universität München, Munich, Germany; Biomedical Center (BMC), Faculty of Medicine, Ludwig-Maximilians-Universität München, Martinsried, Germ…
- Department of Chemical and Structural Biology, Weizmann Institute of Science, Rehovot, Israel.
- Department of Molecular Cell Biology, Weizmann Institute of Science, Rehovot, Israel.
- Department of Veterinary Resources, Weizmann Institute of Science, Rehovot, Israel.
Förderung
- European Research Council
Zitieren
APA
Shalita, R., Ben Yehuda, M., Gur, C., Frid, Y., McGrath, S., Suhler, R., Bolokan, L., Eisenberg, V., Eshed, R. S., Shlomi-Loubaton, S., Tofield, A., Vardy, K., Zada, M., Kurilovich, A., David, E., Jaitin, D., Mazuz, K., Avellino, R., Tzemach, R., …, & Amit, I. (2026). Localized PD-1 CAR T therapy reprograms neuroinflammation. Cell. https://doi.org/10.1016/j.cell.2026.06.036
Vancouver
Shalita R, Ben Yehuda M, Gur C, Frid Y, McGrath S, Suhler R, et al. Localized PD-1 CAR T therapy reprograms neuroinflammation. Cell. 2026. doi:10.1016/j.cell.2026.06.036
BibTeX
@article{Shalita2026,
author = {Shalita, Rotem and Ben Yehuda, Maya and Gur, Chamutal and Frid, Yasmin and McGrath, Sarah and Suhler, Roni and Bolokan, Lihi and Eisenberg, Vasyl and Eshed, Reut Sharet and Shlomi-Loubaton, Shir and Tofield, Adin and Vardy, Karin and Zada, Mor and Kurilovich, Anna and David, Eyal and Jaitin, Diego and Mazuz, Kfir and Avellino, Roberto and Tzemach, Reut and Kuznetsov, Yuri and Fellus-Alyagor, Liat and Levy-Barda, Adva and Mundt, Sarah and Rosenzweig, Rina and Schreiner, Bettina and Peters, Anneli and Stadelmann, Christine and Zwicky, Pascale and Yarkoni, Adi Wilf and Ingelfinger, Florian and Amit, Ido},
title = {Localized PD-1 CAR T therapy reprograms neuroinflammation},
journal = {Cell},
year = {2026},
doi = {10.1016/j.cell.2026.06.036}
}
EUVIMED